J. S. Forman, S. R. Negrin, A. Hj, R. F. Appelbaum, and . Thomas, Hematopoietic Cell Transplantation, 406 Fifth Edition, 2016.

F. R. Appelbaum and E. D. Thomas, Thomas' hematopoietic cell transplantation : stem cell 409 transplantation, vol.410, p.3, 2009.

A. Gratwohl, H. Baldomero, M. Aljurf, M. C. Pasquini, L. F. Bouzas et al., Hematopoietic 412 stem cell transplantation: a global perspective, JAMA : the journal of the American Medical, vol.413, issue.16, pp.1617-1624, 2010.

A. D'souza and C. Fretham, Current Uses and Outcomes of Hematopoietic, CIBMTR Summary Slides, vol.417, 2018.

T. A. Gooley, J. W. Chien, S. A. Pergam, S. Hingorani, M. L. Sorror et al., Reduced mortality 420 after allogeneic hematopoietic-cell transplantation, The New England journal of medicine, vol.421, issue.22, pp.2091-2101, 2010.

E. H. Warren, X. C. Zhang, S. Li, W. Fan, B. E. Storer et al., Effect of MHC and non-MHC 424 donor/recipient genetic disparity on the outcome of allogeneic HCT, Blood, vol.120, issue.14, pp.425-2796, 2012.

T. H. Scheike and M. J. Zhang, Analyzing Competing Risk Data Using the R timereg Package, Journal 607 of statistical software, vol.38, issue.2, 2011.

T. H. Scheike and M. J. Zhang, Flexible competing risks regression modeling and goodness-of-fit

, Lifetime data analysis, vol.14, issue.4, pp.464-483, 2008.

T. Scheike, M. Zhang, and T. Gerds, Predicting cumulative incidence probability by direct binomial 614 regression, Biometrika, vol.95, issue.1, pp.205-220, 2008.

T. Therneau and P. Grambsch, Modeling Survival Data: Extending the Cox Model, vol.617, p.49, 2000.

K. Fleischhauer, B. E. Shaw, T. Gooley, M. Malkki, P. Bardy et al., Effect of T-cell-epitope 619 matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a 620 retrospective study. The Lancet, Oncology, vol.13, issue.4, pp.366-374, 2012.

P. Peduzzi, J. Concato, A. R. Feinstein, and T. R. Holford, Importance of events per independent 624 variable in proportional hazards regression analysis. II. Accuracy and precision of regression 625 estimates, Journal of clinical epidemiology, vol.48, issue.12, pp.1503-1510, 1995.

P. Peduzzi, J. Concato, E. Kemper, T. R. Holford, and A. R. Feinstein, A simulation study of the number 629 of events per variable in logistic regression analysis, Journal of clinical epidemiology, vol.630, issue.12, p.52, 1996.

R. Team, R: A language and environment for statistical computing, Vienna, Austria: R 633 Foundation for Statistical Computing, vol.635, p.53, 2010.

J. Wu, N. J. Chalupny, T. J. Manley, S. R. Riddell, D. Cosman et al., Intracellular retention of the 636 MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 637 glycoprotein, Journal of immunology, vol.170, issue.8, p.12, 2003.

J. Spreu, T. Stehle, and A. Steinle, Human cytomegalovirus-encoded UL16 discriminates MIC 641 molecules by their alpha2 domains, Journal of immunology, vol.177, issue.5, pp.3143-3149, 2006.

J. Nikolich-zugich, F. Goodrum, K. Knox, and M. J. Smithey, 647 56. de la Camara R. CMV in Hematopoietic Stem Cell Transplantation. Mediterranean journal of 649 hematology and infectious diseases, vol.646, p.2016031, 2016.

A. E. Broers, R. Van-der-holt, J. W. Van-esser, J. W. Gratama, and S. Henzen-logmans,

V. Boumeester, Increased transplant-related morbidity and mortality in CMV-654 seropositive patients despite highly effective prevention of CMV disease after allogeneic T-655 cell-depleted stem cell transplantation, Blood, vol.95, issue.7, pp.2240-2245, 2000.

N. Cantoni, H. H. Hirsch, N. Khanna, S. Gerull, A. Buser et al., Evidence for a bidirectional 659 relationship between cytomegalovirus replication and acute graft-versus-host disease. 660 Biology of blood and marrow transplantation : journal of the American Society for Blood, p.661

, Marrow Transplantation, vol.16, issue.9, pp.1309-1314, 2010.

, HLA: Human Leukocyte Antigen. All clinical variables of the table were 689 used for adjustment in the multivariate models

, * P-values were determined with Pearson's Chi square test or Fisher's exact test for small 691 sample sizes

, ? Patients received their transplant in six centers of the Francophone Society of Bone 693

, SFGM-TC) (1 to 6; N =682) and in three Dutch 694 centers that are part of the Europdonor operated by the Matchis Foundation network, Marrow Transplantation and Cell Therapies

, ? in vivo T-cell depletion was performed by the addition of anti-thymocyte globulin (ATG) or 697

, Alemtuzumab to the conditioning regimen

, Other diseases include multiple myeloma, Hodgkin lymphoma, Fanconi anemia, aplastic 699 anemia, chronic lymphocytic leukemia, plasma cell leukemia, other acute leukemias

, Late 702 corresponds to second or higher complete remissions, accelerated phases, partial 703 remissions, progressions, primary induction failures, relapses or stable diseases. Not 704 applicable corresponds to bone marrow failure (aplastic anemia, Fanconi anemia)

*. Hla, DPB1 matching was defined at the T-cell-epitope matching level 49 with typing data at 707 2 nd field resolution following the World Health Organization official nomenclature

G. Acute and . Ii-iv,

G. Acute and . Iii-iv,

, Chronic GVHD, vol.1

, Overall survival, vol.1

. Non-relapse,

, GVHD: Graft-712 versus-host disease. * All models were adjusted for patient's age, patient-donor sex, patient-713 donor serological status for cytomegalovirus, year of transplantation, time to transplantation, 714 transplantation center, source of stem cells, conditioning regimen, GVHD prophylaxis, 715 treatment with anti-thymocyte globulin or Alemtuzumab, HLA-DPB1 matching status, disease 716 category and severity at transplantation. ? Transplantations performed for non, p.717